公司概述
Generation Bio Co. operates as a biotechnology entity dedicated to discovering, developing, and commercializing redosable therapeutics designed to reprogram T cells in vivo, thereby reducing or eliminating the production and persistence of autoreactive T cells. The company functions within the broader healthcare sector and specifically the biotechnology industry, where innovation in cell-targeted lipid nanoparticles (ctLNP) is utilized to selectively deliver small molecules for targeted therapeutic delivery. In terms of scale, the company holds a market capitalization of $35.98 million, generated $15.27 million in annual revenue, and employs a workforce of 115 individuals. These financial metrics indicate that the company maintains a relatively small market presence compared to large-cap pharmaceutical peers, positioning it as a mid-stage development entity where revenue figures reflect early commercialization efforts rather than mature market dominance.
财务健康
The company reported a trailing twelve-month revenue of $15.27 million, yet recorded a net income loss of $62,627,000, creating a significant gap that reveals a high-cost structure typical of biotechnology firms in the research and development phase. This disparity between revenue and net income is further highlighted by an EBITDA of $-76,380,000, indicating that operating expenses substantially exceed earnings before interest, taxes, and amortization. The company's free cash flow stands at $-40,196,752, which signifies a heavy burn rate that limits immediate financial flexibility without continued external capital injection or operational efficiency gains. Margin analysis shows a gross margin of -212.2%, an operating margin of -2020.0%, and a profit margin of 0.0%, all negative figures that point to substantial cost pressures in production and operational overhead relative to current sales levels. Regarding liquidity, the company holds $89.62 million in cash against $26.10 million in debt, resulting in a debt-to-equity ratio of 51.61, which suggests a balance sheet that is leveraged but supported by a substantial cash reserve to service obligations. The current ratio is 4.44, indicating a strong short-term liquidity position where current assets significantly exceed current liabilities. Furthermore, the return on equity is -80.8% and the return on assets is -27.4%, metrics that reveal that management has not yet generated positive returns on the capital invested by shareholders or asset base.
估值评估
Valuation metrics for Generation Bio Co. include a trailing P/E ratio that is listed as N/A due to losses, while the forward P/E is -3.99, implying that analysts project continued earnings contraction or that earnings have not yet turned positive. The price-to-book ratio is 0.71, indicating that the market values the company at less than its book value, which often suggests a market discount rather than a premium over tangible assets. Alternative valuation multiples such as a price-to-sales ratio of 2.36 and an EV/EBITDA of 0.36 provide insight into the company's valuation relative to revenue and enterprise value, suggesting a low multiple environment typical for loss-making biotech firms. The stock's 52-week trading range spans from a low of $3.00 to a high of $7.60, and the current price sits below the 52-week high, reflecting recent volatility within this defined band. The beta value is 2.01, which indicates that the stock price exhibits high volatility relative to the broader market, moving with significantly greater amplitude than the overall index.
Growth & Income
The company experienced a revenue growth rate of -78.9% year-over-year, while earnings growth is listed as N/A due to the absence of positive net income. This negative revenue trajectory implies a contraction in sales, and since earnings are already negative, the concept of earnings growing faster or slower than revenue is currently moot as both metrics reflect decline or non-profitability. As a non-dividend payer, the company reports a dividend yield of N/A and a payout ratio of 0.0%, meaning it does not distribute cash to shareholders but instead reinvests any available resources, though currently insufficient, into its growth initiatives. The overall growth and income profile is characterized by significant revenue contraction and a lack of dividend income, reflecting the high-risk, high-reward nature of a biotechnology company still navigating the path to commercial viability.